SOUTH SAN FRANCISCO, Calif., April 13, 2026 (GLOBE NEWSWIRE) — Allogene Therapeutics, Inc. (Nasdaq: ALLO) at this time introduced that it intends to supply and promote, in an underwritten public providing and topic to market and different circumstances, $175 million of shares of its widespread inventory. All the shares are being supplied by Allogene. As well as, Allogene intends to grant the underwriters for the providing a 30-day choice to buy as much as an extra $26.25 million of the shares of its widespread inventory supplied within the public providing. There may be no assurance as as to whether or when the providing could also be accomplished, or as to the precise measurement or phrases of the providing.
Allogene expects to make use of the online proceeds from this providing for normal company functions, which can embrace medical trial bills, analysis and growth bills, normal and administrative bills, and capital expenditures.
Goldman Sachs & Co. LLC, Jefferies and TD Cowen are appearing because the joint book-running managers for the providing. TPG Capital BD, LLC is appearing as co-manager for the providing.
This press launch shall not represent a suggestion to promote or the solicitation of a suggestion to purchase these securities, nor shall there be any sale of those securities in any state or different jurisdiction wherein such provide, solicitation or sale could be illegal previous to the registration or qualification below the securities legal guidelines of any such state or different jurisdiction.
About Allogene TherapeuticsAllogene Therapeutics, with headquarters in South San Francisco, is a clinical-stage biotechnology firm pioneering the event of allogeneic chimeric antigen receptor T cell (AlloCAR T) merchandise for most cancers and autoimmune illness. Led by cell remedy veterans making use of confirmed CAR T expertise, Allogene is growing a pipeline of off-the-shelf CAR T cell product candidates with the objective of delivering available cell remedy on-demand, extra reliably, and at larger scale to extra sufferers.
More Read
Cautionary Observe on Ahead-Trying Statements Sure statements on this press launch are forward-looking statements that contain quite a lot of dangers and uncertainties. These statements could also be recognized by introductory phrases akin to “may,” “expects,” “goal,” “intend,” “will,” “would,” “subject to” or phrases of comparable which means, or by the truth that they don’t relate strictly to historic or present information. Such forward-looking statements embrace statements relating to Allogene’s expectations with respect to the completion, timing and measurement of the proposed public providing, the usage of proceeds from the providing and granting the underwriters a 30-day choice to buy further shares. For such statements, Allogene claims the safety of the Personal Securities Litigation Reform Act of 1995. Precise occasions or outcomes could differ materially from Allogene’s expectations. Elements that might trigger precise outcomes to vary materially from the forward-looking statements embrace, however aren’t restricted to, dangers and uncertainties related to market circumstances and the satisfaction of customary closing circumstances associated to the proposed providing, and people components disclosed in Allogene’s filings with the SEC, together with its Annual Report on Kind 10-Ok for the 12 months ended December 31, 2025, filed with the SEC on March 12, 2026, and different filings that Allogene could make once in a while with the SEC. These forward-looking statements characterize Allogene’s judgment as of the time of this launch. Allogene disclaims any intent or obligation to replace these forward-looking statements, apart from as could also be required below relevant regulation.
